News

10May

TAVEC has received seed funding from Sanderling Ventures

The ability to penetrate the dense structure of solid tumors has been presented a remarkably difficult for treating these tumors. Tavec’s exosome mediated technology enables.. Read More →
18Apr

THERILLIA acquires TAVEC Pharmaceutical and moves it to Montreal

Therillia Development Co., a Montreal-based subsidiary of Sanderling Ventures Canada, an investor in early-stage biotech companies, has acquired TAVEC Pharmaceuticals, the leading therapeutic exosome company.. Read More →
15Apr

Tavec to further clinical development of miRNA loaded exosomes to treat cancer

Tavec Pharmac, (Tavec) announced today the completion of a worldwide, exclusive license with The Johns Hopkins University for exosome mediated gene therapy to treat cancer.. Read More →